CRISPR Therapeutics
CRSP
CRSP
485 hedge funds and large institutions have $3.67B invested in CRISPR Therapeutics in 2026 Q1 according to their latest regulatory filings, with 80 funds opening new positions, 174 increasing their positions, 114 reducing their positions, and 57 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
0.09% more ownership
Funds ownership: 80.26% → 80.35% (+0.09%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
9% less capital invested
Capital invested by funds: $4.03B → $3.67B (-$358M)
Holders
485
Holding in Top 10
6
Calls
$127M
Puts
$105M
Top Buyers
| 1 | +$249M | |
| 2 | +$53.4M | |
| 3 | +$41.8M | |
| 4 |
Millennium Management
New York
|
+$18.3M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$13.1M |
Top Sellers
| 1 | -$248M | |
| 2 | -$40.2M | |
| 3 | -$22.5M | |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$21.8M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$14.5M |
